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ABSTRACT
Chronic obstructive pulmonary disease (COPD)
is associated with high morbidity and mortality.
COPD is typified by persistent, progressive
airflow limitation and a range of respiratory
and systemic symptoms such as breathlessness,
coughing, wheezing, depression, anxiety,
general fatigue, and sleeping difficulties.
Despite receiving treatment for COPD, many
patients suffer from regular symptoms that
affect their daily lives and lead to increased
morbidity. These symptoms vary in severity,
frequency, and type, and can occur at any time
throughout the 24-h day, with over half of
patients with COPD experiencing symptoms in
the morning, during the day, and at nighttime.
Despite the prevalence of symptoms, patient
and physician perception of the impact of
COPD symptoms on patients’ lives is not
always in concordance. Dual bronchodilator
therapy with a long-acting muscarinic
antagonist (LAMA) and long-acting beta
agonist (LABA) has the potential to treat the
symptoms of COPD in addition to improving
lung function. This review therefore examines
the burden of symptoms experienced
throughout the day by patients with COPD
and the evidence for combined LAMA/LABA
treatment in terms of symptom management.
As patients with COPD experience varying
symptoms throughout the course of their
disease, the role of tailoring treatment to the
individual needs of the patient is also
examined. We conclude that the symptoms of
COPD are troublesome, variable, can occur
during all parts of the 24-h day, and have a
substantial impact on patients’ health status
and quality of life. In order to provide effective,
patient-orientated care, patients with COPD
should be evaluated on the basis of lung
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function, the frequency of symptoms, and
patient-perceived impact of symptoms on their
lives. Therapy should be chosen carefully based
on individualized assessment, ensuring
personalization to the individual needs of the
patient.
Keywords: Aclidinium/formoterol; COPD;
Dual bronchodilator; LABA; LAMA; Respiratory
INTRODUCTION
Chronic obstructive pulmonary disease (COPD)
is predicted to be the fourth leading cause of
morbidity and mortality around the world by
2030, and confers an increasing socioeconomic
burden [1]. The World Health Organisation
estimates that, globally, 64 million people had
moderate to severe COPD in 2004 [2], although
the total burden of COPD is thought to be
underestimated due to diagnosis usually only
occurring when the disease is clinically
apparent and moderately advanced [3]. The
rise in morbidity and mortality from COPD
over the next two decades is expected to be
most dramatic in Asia and Africa, due in part to
the progressive increase in the prevalence of
smoking in these regions [2, 4].
COPD is characterized by expiratory airflow
obstruction, reduced elastic recoil, and reduced
parenchymal tethering [5]. Reduced elastic
recoil leads to hyperinflation of the lungs,
which impairs chest wall and diaphragm
mechanics, making breathing more difficult
and increasing dyspnea. As well as dyspnea,
patients with COPD experience a range of
symptoms, both respiratory and systemic;
these symptoms and their severity can be
highly variable [5].
There are currently several treatment
options/actions for patients with COPD that
can help to reduce and/or manage their
symptoms, including pharmacologic therapies,
pulmonary rehabilitation, and smoking
cessation, all of which can also improve
bronchodilation, reduce the frequency and
severity of exacerbations, and improve health
status and exercise tolerance [5]. However,
many patients still suffer from regular
symptoms that affect their daily lives and lead
to increased morbidity. Therefore, selecting the
right therapies and optimizing treatment to
reduce airway obstruction and improve
symptoms is key in improving quality of life
for each patient with COPD.
This review examines the burden of
symptoms experienced throughout the day by
patients with COPD, the evidence for combined
long-acting muscarinic antagonist and
long-acting beta agonist (LAMA/LABA)
treatment in terms of symptom management,
and the role of tailoring treatment to the
specific, individual needs of the patient.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies, and does not involve any new studies of




Patients with COPD experience a range of
symptoms that can vary greatly in severity.
Symptoms can be respiratory-related, such as
breathlessness, phlegm, cough, wheezing, and
chest-tightness, as well as less specific
symptoms relating to comorbidity, such as
depression, anxiety, general fatigue,
despondency, and sleeping difficulties [6].
Importantly, the majority of patients with
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COPD frequently continue to experience
symptoms despite receiving treatment [6, 7].
COPD symptoms can vary in frequency,
severity, and type throughout the 24-h period,
often depending on the age of the patient and
the severity of their disease, with morning and
nighttime symptoms reported as being
particularly troublesome [6, 8, 9]. When
patients do experience variability or worsening
of their symptoms, many do not know how to
self-manage this therapeutically, and a large
proportion simply continue to use their
medication in the same way [6]. Table 1
provides a summary of studies of symptom
variability in patients with COPD.
24-Hour Symptom Profile
COPD symptoms and variation in symptoms
over a 24-h day were investigated in the ASSESS
observational study, which explored the
relationship between the 24-h symptom
profile and patient-reported outcomes (PROs),
using a novel, 33-item questionnaire developed
by the sponsor of the study [7]. The study
evaluated the prevalence and severity of
symptoms over three periods: in the early
morning, during the daytime, and at night [7].
Severity of airflow obstruction, health status,
anxiety, depression, sleep quality, and physical
activity were also evaluated to gauge the impact
of symptoms. Over 90% of patients experienced
COPD symptoms during at least one period of
the 24-h day, and 57% of patients reported
experiencing symptoms during all three
periods. Stratification by disease severity
revealed that even among patients with mild
COPD, over 80% experienced symptoms during
at least one part of the 24-h day [7].
In ASSESS, a significant relationship was seen
between severity of disease and symptoms
during the early morning and the daytime,
with a higher percentage of patients with severe
or very severe COPD experiencing symptoms in
the morning and during the day versus those
with mild or moderate disease [7]. However, the
proportion of patients with nighttime
symptoms was similar in patients with mild,
moderate, severe, and very severe disease [7, 10].
Nearly two-thirds of patients experienced
nighttime symptoms, regardless of the severity
of the disease (Fig. 1a) [7].
The prevalence of individual symptoms also
varied throughout the 24-h period, with
breathlessness being most prevalent overall,
reported in around 70% of patients. In the
early morning, coughing, bringing up phlegm,
and breathlessness were reported in around half
of patients. During the day, over two-thirds of
patients with COPD experienced breathlessness,
around half experienced coughing symptoms,
and just under half reported bringing up
phlegm. During the night, coughing was most
prevalent amongst patients with COPD, being
reported in around 42% of patients, with
bringing up phlegm, breathlessness, and
wheezing also reported in around a third of
patients [7] (Fig. 1b).
A comparison between symptoms and
COPD Assessment Test (CAT) scores in
patients with COPD from ASSESS showed
that patients with symptoms throughout the
whole 24-h day had the worst health status
versus those with no symptoms or with
symptoms only in one part of the day [7].
The difference in CAT scores between patients
with symptoms in all three parts of the 24-h
day compared with patients without
symptoms surpassed two units, the proposed
estimate for a minimal clinically important
difference (MCID) [7, 11]. In addition, both
anxiety and depression levels were highest in
patients who had symptoms in all three parts
of the 24-h day and lowest in patients with no
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Fig. 1 a Percentage of patients experiencing symptoms in
the early morning, the daytime, and at night, according to
COPD severity; b prevalence of individual COPD
symptoms throughout the 24-h day. COPD chronic
obstructive pulmonary disease. Adapted from Miravitlles
et al. 2014 (Copying and redistribution of the materials
allowed in any medium or format: CC BY-NC 4.0) [7]
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symptoms, or symptoms during only one part
of the day [7].
Morning Symptoms
Symptoms of COPD experienced in the
morning are known to impact on the ability of
patients to carry out daily activities, such as
walking up and down stairs, washing, and
getting dressed [8], with a potential knock-on
effect on the time of taking first COPD
medications: one study showed that 35% of
patients took their medication either whilst still
in bed or immediately after getting up to relieve
their COPD symptoms [8]. Patients with
morning symptoms have also been shown to
have higher CAT scores and lower EuroQol five
dimensions questionnaire scores than those
without morning symptoms, indicating a
more serious impact on quality of life [12, 13];
these patients are also at increased risk of
experiencing exacerbations [13].
Nighttime Symptoms
Symptoms of COPD experienced during the
night can contribute to sleep disturbance,
including difficulty falling asleep, staying
asleep, and waking feeling tired, with
symptoms affecting patients regardless of
COPD severity [10]. In the ASSESS study, one
or more symptoms was associated with a greater
sleep impairment score at all three points
during the 24-h day [7]. Such impairment or
disruption of sleep is associated with reduced
quality of life, as indicated by the Pittsburgh
Sleep Quality Index score which is a significant
predictor of disease-specific quality of life (as
assessed using the St George’s Respiratory
Questionnaire [SGRQ]) [14]. It is worth noting,
however, that, in some cases, sleep disturbance
could also be attributed to other causes, such as
a side effect of medication for heart failure or
prostate hypertrophy [15, 16].
In terms of predicted outcomes for patients
with COPD, it has been reported that sleep
disturbances among patients with COPD are
predictive of poorer survival and increased rates
of exacerbations and hospital admissions
[17–19]. It has also been documented that the
level of dyspnea correlates significantly to the
5-year survival rate of patients, and was more
discriminating than percentage of predicted
forced expiratory volume in 1 s (FEV1) in
predicting 5-year survival, suggesting that
consideration of symptoms of breathlessness
alongside airway obstruction may provide a
better prognostic indicator of COPD mortality
[18, 20].
Patient and Physician Perceptions
of COPD Symptoms
While a substantial body of evidence
demonstrates the importance and impact of
symptoms to patients, patient and physician
perceptions of this impact may not always
correspond. Overall, patients appear to
underestimate their morbidity, and are
possibly undertreated as a result [21]. Based on
an objective breathlessness scale, in patients
classified as too breathless to leave the house, a
third described their condition as mild to
moderate [21]. In another study, while both
physicians and their patients identified
breathlessness, fatigue, and coughing as the
main symptoms of COPD that had most effect
on patients’ lives [22], within the other
symptom categories, such as expectoration,
dry mouth, despondency, wheezing, sleeping
difficulties, and chest pain, there were varying
perceptions (in terms of rank) of the impact of
these symptoms [22]. There was a greater degree
of physician-patient concordance in patients
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with more severe COPD. Another study
observed good concordance between the
frequency of nighttime symptoms reported by
patients and physicians, but also found that
physicians significantly underestimated the
impact of COPD symptoms on patients’ lives
[10].
As current treatment options still lack
control over symptoms, there remains a need
for additional therapies. The exploration of
treatment options that target both airway
obstruction and COPD symptoms throughout
the 24-h day may therefore provide patients
with relief from the substantial impact that
these symptoms can have on their health status.
THE UTILITY OF DUAL
BRONCHODILATION IN COPD
Most patients with COPD report
slight-to-moderate breathlessness across all
severities of the disease with either a LAMA or
a LABA, which are the current first-line Global
Initiative for Chronic Obstructive Lung Disease
(GOLD)-recommended treatments for patients
with COPD [5]. LAMAs and LABAs have two
different but complementary mechanisms of
action [23, 24]: muscarinic antagonists block M1
and M3 receptors at the parasympathetic
ganglia and on smooth muscle cells which
inhibits the contraction of airway smooth
muscle, while b2 agonists stimulate b2
receptors on smooth muscle cells which leads
to the relaxation of airway smooth muscle via
an independent but linked mechanism.
Combination therapy with a LAMA and a
LABA therefore has the potential to improve
bronchodilation and symptoms in those
patients whose COPD is not sufficiently
controlled by monotherapy. The currently




glycopyrrolate/formoterol has recently been
approved in the USA [25].
Dual Bronchodilator Therapy and Lung
Function
The lung-function benefits of these LAMA/
LABA combination therapies are well
established, with several large phase III clinical
studies demonstrating that dual therapy
improves trough, peak, and post-dose FEV1
versus placebo [26–30]. Data from these
studies also show rapid and sustained
improvements in trough FEV1 with dual
therapies versus monotherapies, with the
improvements in the region of 45–85 mL with
aclidinium/formoterol, 52–95 mL with
umeclidinium/vilanterol, 12–88 mL with
tiotropium/olodaterol, and 70–90 mL with
indacaterol/glycopyrronium [26–30]. A
comprehensive review of dual therapy and a
meta-analysis of dual bronchodilation with
LAMA/LABA for the treatment of stable COPD
have both shown that these treatments are
effective with regards to lung function [31, 32].
ACLIFORM [33] and AUGMENT [28] were two
24-week, randomized, double-blind studies
assessing the efficacy and safety of the
combined LAMA/LABA therapy,
aclidinium/formoterol, in patients with
moderate-to-severe COPD. Post hoc analyses
from ACLIFORM and AUGMENT determined
that dual therapy with a LAMA/LABA improved
lung function irrespective of severity of airflow
obstruction, patient age, or use of concomitant
inhaled corticosteroid (ICS) [34–36].
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Dual Bronchodilator Therapy
and Breathlessness
The Transition Dyspnea Index (TDI) is an
interviewer-administered tool which assesses
deterioration or improvement in
breathlessness [37]. The TDI has been utilized
in several studies which have reported a
reduction in breathlessness in patients with
COPD following treatment with dual therapies
versus placebo [26, 28–30, 38, 39]. The potential
for interviewer bias associated with the TDI has
been addressed following subsequent
development of a validated self-administered
computerized version [40–43]. Many studies
consistently report improvements with dual
therapies that exceed one unit, the MCID for
TDI focal score [28, 29, 38, 39], whereas
monotherapies are unable to consistently
show the same improvements [44].
Furthermore, responder analysis has shown
that a greater proportion of individuals
achieve a response [1 unit with dual
bronchodilatory therapy compared to
monotherapies [29, 38]. Additionally, in two
of these studies, the PRO Shortness of Breath
with Daily Activities (SOBDA) questionnaire
scoring system was utilized to assess changes
in breathlessness in patients with COPD, and
showed that umeclidinium/vilanterol
treatment groups saw improvements in their
SOBDA score versus placebo [29, 45]. The
SOBDA questionnaire is a more recently
developed outcome measure that has been
validated and uses a patient daily diary to
better capture the inherent variability of
dyspnea that is not adequately accounted for
by other dyspnea-related PROs [45, 46].
Moreover, it can be further differentiated from
other dyspnea-related PROs in that it was
specifically developed to support FDA
recommendations.
Dual Bronchodilator Therapy
and EXACT-Respiratory Symptoms (E-RS)
Score
Since reducing the severity of respiratory
symptoms is a key goal in the treatment of
COPD, it is important to use standardized
methods for quantifying daily respiratory
symptoms in clinical trials. EXAcerbations of
Chronic obstructive pulmonary disease Tool
(EXACT)-Respiratory Symptoms (E-RSTM1) is a
PRO designed to assess the effect of treatment
on the severity of symptoms (breathlessness,
cough and sputum, and chest pains) in patients
with COPD in clinical trials [47–49]. The E-RS
has several advantages over other COPD-specific
health status questionnaires, including use of
daily scores to reduce recall bias, capture of
daily variability in symptoms, and simultaneous
assessment of exacerbation data and respiratory
symptoms [47]. In two studies,
aclidinium/formoterol produced significantly
greater improvements in E-RS total score
versus both placebo and the monotherapies
[28, 39].
Dual Bronchodilator Therapy
and Nighttime and Morning Symptoms
Although nighttime symptoms are known to
negatively impact on health status, sleep
disturbances, and healthcare resource
utilization, current monotherapies may not
adequately control these symptoms.
The Nighttime Symptoms of COPD
Instrument (NiSCI) is a reliable, validated
self-completed electronic daily diary
(measuring nighttime symptom occurrence
and severity, nocturnal awakening due to
1 The E-RSTM is owned by Evidera. Permission to use this
instrument may be obtained from Evidera
(exactpro@evidera.com).
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COPD symptoms, and nighttime rescue
medication use in patients with COPD) that
was recently developed to support treatment
benefit endpoints in global clinical trials
[50, 51]. The use of a daily diary within the
NiSCI is intended to better capture the
variability of nighttime symptoms and
minimize recall bias; however, research is
ongoing to define responders and evaluate
COPD treatment responsiveness. Dual therapy
with aclidinium/formoterol has been shown to
produce significant improvements in overall
nighttime symptom severity (measured using
the NiSCI score) versus placebo, which
aclidinium and formoterol alone did not
achieve [28]. Additionally, nighttime symptom
severity has been shown to significantly
improve with aclidinium/formoterol versus
aclidinium, with numerical improvements
reported with aclidinium/formoterol versus
formoterol [28]. This improvement in
nighttime symptom severity with dual therapy
has also been mirrored in patients receiving
indacaterol/glycopyrronium, who experienced
a significantly higher percentage of nights
without awakenings versus placebo [38].
The Early Morning Symptoms of COPD
Instrument (EMSCI) was also recently developed
to support treatment benefit endpoints in clinical
research and has demonstrated both reliability
and validity in evaluating early-morning
symptoms in COPD [52]. Dual therapy was
found to improve early-morning symptom
severity. In a 24-week study of patients with
stable COPD, aclidinium/formoterol produced
significant improvements in EMSCI score versus
placebo, a result that was not replicated following
treatment with monotherapies [28]. The dual
therapy also significantly improved
early-morning symptom severity versus
monotherapies at some of the time points
assessed [28].
Dual Bronchodilator Therapy and Quality
of Life
Dual LAMA/LABA bronchodilator therapy
appears to have a positive outcome on quality
of life as assessed by the SGRQ total score. When
compared with placebo, aclidinium/formoterol,
umeclidinium/vilanterol, and indacaterol/
glycopyrronium have all been shown to
improve SGRQ total scores [26–30]. AUGMENT
and ACLIFORM compared patients whose
improvement in SGRQ was equal to or greater
than four units, the MCID for SGRQ. A
statistically greater proportion of patients
receiving aclidinium/formoterol achieved the
MCID than patients receiving placebo [28, 39].
Additionally, improvements in SGRQ total score
were reported for indacaterol/glycopyrronium
versus tiotropium monotherapy, and with
tiotropium/olodaterol versus tiotropium and
olodaterol monotherapy [27, 30]. Although the
SGRQ provides a comprehensive assessment of
COPD health status and has been widely used in
clinical trials, it is considered overly complex for
routine use in clinical practice; alternatives such
as the COPD Assessment Test and the COPD
Control Questionnaire are considered more
appropriate [5, 53].
Despite the existence of effective
pharmacological treatments, patient adherence
to therapy is often poor [54], and may be due to
adverse events (AEs) associated with treatment.
Encouragingly, the safety and tolerability




appear to be similar to those of the individual
monotherapy components, with
nasopharyngitis, headache, dry mouth, cough,
and oropharyngeal pain reported as the most
common AEs [55–58].
292 Adv Ther (2017) 34:281–299
In summary, when compared with
monotherapy treatments, LAMA/LABA
treatments may have the potential to offer
superior bronchodilation across patient
subgroups, with reduced symptom burden and
relief-medication use, and with no increase in
drug-related AEs [31]. The risks and benefits of
each treatment option should be considered
when deciding on optimal disease management
for individual patients.
THE RIGHT TREATMENT
FOR THE RIGHT PATIENT
Individual patients with COPD may require
different treatment approaches at different
stages of their disease [5]. In order for the
most appropriate treatment to be selected,
patients should be assessed and treatment
decisions made on a case-by-case basis; the
GOLD report outlines strategies for the
pharmacological management of COPD [5].
Those patients who are most suited to
treatment with dual bronchodilator therapy
need to be identified and decisions made on
whether treatment should be escalated and
which drugs to use. In the case of a patient
newly diagnosed with COPD, it would be
appropriate to prescribe either a LAMA or a
LABA as monotherapy. Indeed, LAMA and
LABA bronchodilator monotherapy currently
provide the mainstay for treatment-naı¨ve,
moderately symptomatic patients with little/
no exacerbation history; these therapies are
effective at increasing FEV1, reducing
symptoms, and increasing quality of life versus
placebo, with no significant difference between
the two treatment options [59–61]. Therefore,
when choosing a LAMA or LABA therapy in
newly diagnosed, treatment-naı¨ve patients, the
focus may be on patient preference (if any is
expressed), with the option to switch to the
alternative therapy should any AEs be
experienced.
However, should a patient remain
symptomatic following a LABA or LAMA, then
a decision must be made between initiating
treatment with a LAMA/LABA or a LABA/ICS
dual therapy (or indeed a LAMA/LABA/ICS
triple therapy). When deciding whether to
treat with an ICS, it would be prudent to
consider the potential for AEs that are well
documented with this class of therapy [62],
including pneumonia, increased fractures,
diabetes, and other steroid-related effects [10].
Therefore, it may be pertinent to avoid
steroid-related AEs by prescribing a LAMA/
LABA dual therapy instead, if it had equivalent
efficacy to treatment with LABA/ICS.
LAMA/LABA OR LABA/ICS?
Several studies have compared dual therapy
with LAMA/LABA to that of LABA/ICS,
including AFFIRM (aclidinium/formoterol
versus salmeterol/fluticasone in patients with
stable COPD [63, 64]), ILLUMINATE
(indacaterol/glycopyrronium versus salmeterol/
fluticasone in patients with stable COPD [65]),
LANTERN (indacaterol/glycopyrronium versus
salmeterol/fluticasone in patients with
moderate to severe stable COPD [66]), a study
which compared umeclidinium/vilanterol with
fluticasone/salmeterol in patients with
stable COPD [67], a study which compared
umeclidinium/vilanterol with salmeterol/
fluticasone [68], and ENERGITO (tiotropium/
olodaterol versus salmeterol/fluticasone in
patients with moderate to severe COPD) [69].
These six studies have all demonstrated that
lung function was significantly improved with
LAMA/LABA treatment compared with LAMA/
Adv Ther (2017) 34:281–299 293
ICS treatment [63–69]. Additionally,
ILLUMINATE reported a significant increase in
TDI focal score with LAMA/LABA versus LABA/
ICS [65], while the other studies have
comparable TDI focal score improvements for
both treatment groups, all of which were
clinically meaningful [63, 64, 66, 68, 70].
These studies were not performed using
inclusion criteria to specifically only include
patients with COPD with an exacerbation
history in the previous year; this gap in
knowledge has been filled by the FLAME
study, showing that LAMA/LABA had a greater
impact in exacerbation prevention than ICS/
LABA in this specific COPD subgroup [71]. With
studies showing LAMA/LABA treatment at least
as effective as LABA/ICS in treating COPD, one
must consider the question: when is it
appropriate to prescribe ICS or LABA/ICS to
patients with COPD?
Different therapies may be more appropriate
than others for individual patients, and
treatments should be chosen carefully, based
on a thorough assessment of each patient.
Several COPD phenotypes have been identified
and validated against clinical outcomes or
response to treatment, including: (1) alpha-1
antitrypsin deficiency that may respond to
augmentation therapy; (2) emphysema/
hyperinflation that is responsive to lung
volume reduction surgery; and (3) frequent
exacerbators (C2 per year) who respond to
therapies reducing exacerbation frequency
[72]. Additional COPD phenotypes have been
proposed including, but not limited to, a rapid
lung function decline phenotype, persistent
inflammation phenotype, and a chronic
bronchitis phenotype [72].
There is evidence to suggest that patients
with an elevated blood eosinophil count may
achieve particular benefit from ICS therapy in
terms of reducing exacerbations; however, an
appropriate eosinophil count threshold to
identify such a patient subgroup has yet to be
established [73]. Further investigations into
patient grouping, identifying patients with
COPD who will respond more favorably to
certain treatments, and measurable biomarkers
are ongoing. For example, a 12-week,
randomized, open-label, parallel-group study
(NCT02546349) of LABA/ICS versus LAMA
stratified by high and low exhaled nitric oxide
levels (C23.5 vs. \23.5 ppb), which is a
surrogate marker for eosinophilic airway
inflammation, is underway and findings are
keenly anticipated [74].
It has been proposed that LAMA/LABA dual
bronchodilation is an appropriate intervention
in patients with persistent breathlessness and
exercise impairment that remain troublesome
despite LAMA monotherapy [73]; however, no
recommendations have been made regarding
prioritising use of one specific LAMA/LABA
therapy over another. No LAMA/LABA is
currently approved in any particular subgroup
of COPD patients and further research via
adequately powered prospective head-to-head
clinical trials would be needed before
advocating a specific LAMA/LABA in a specific
patient subgroup. At present, physicians should
assess their patients to evaluate the individual
burden imposed by COPD on each patient and
consider the available LAMA/LABA evidence
base before selecting an appropriate
therapeutic intervention that will maximize
the likelihood of achieving clinical benefit.
In conclusion, it is well documented that the
symptoms of COPD are troublesome, variable,
can occur during all parts of the 24-h day, and
have a substantial impact on patients’ health
status and quality of life. In order to provide
effective, patient-orientated care, patients with
COPD should be evaluated on the basis of lung
function, the frequency of symptoms, and
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patient-perceived impact of symptoms on their
lives. Many studies demonstrate that dual
bronchodilator therapy has greater efficacy in
improving lung function and symptom
management versus monotherapy, but with
equivalent safety profiles. New analysis of
completed studies also suggests that differing
therapies may be more appropriate than others
for individual patients and that treatments
should be selected carefully based on
patient-by-patient assessment.
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